Drew identified the CARM1 inhibitor EZM2302 (GSK3359088) with potent in vitro activity in preclinical models of aggressive myeloma, and treatment with EZM2302 in MM cell lines inhibited PABP1 and SMB methylation and cellular arrest [141]. The gene discussed is CARM1; the disease is plasma cell myeloma.